Literature DB >> 9692845

Quantitation of the oligosaccharides of human serum IgG from patients with rheumatoid arthritis: a critical evaluation of different methods.

F H Routier1, E F Hounsell, P M Rudd, N Takahashi, A Bond, F C Hay, A Alavi, J S Axford, R Jefferis.   

Abstract

Several different chromatographic methods and a lectin-based assay have been compared for the quantitation of oligosaccharides released from immunoglobulin G (IgG). The analysis of a series of IgG samples purified from the serum of rheumatoid arthritis patients was carried out by these methods to evaluate the percentage of the glycoforms having 0, 1 or 2 galactose residues (G0, G1 and G2) in order to (a) identify the method that can be most widely used for quantitation, (b) accurately define the range of G0 values found in patients with rheumatoid arthritis, and (c) make available a series of characterised standards for distribution to clinical chemistry laboratories. The chromatographic methods involved: release of oligosaccharides by glycoamidase A after protease digestion followed by HPLC analysis of aminopyridine derivatives on reverse phase and normal phase columns; hydrazinolysis treatment with exoglycosidases (G0 mix) and Biogel P4 chromatography of 2-aminobenzamide (2-AB) derivatives; hydrazinolysis and weak anion exchange or normal phase HPLC of 2-AB derivatives; release of oligosaccharides by PNGase F and either Biogel P4 chromatography of 2-AB derivatives or HPAEC-PAD analysis of native oligosaccharides. The G0 values given by these methods compared favourably with each other and a dot blot assay of denatured IgG interaction with Ricinus communis agglutinin and Bandeiraea simplicifolialectin II. The HPLC and HPAEC methods give additional information that may be important in less routine assays.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9692845     DOI: 10.1016/s0022-1759(98)00032-5

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  15 in total

1.  Relationship between CDT and disease activity in rheumatoid arthritis.

Authors:  B Cylwik; A Chludzinska; L Chrostek; E Gruszewska; E Gindzienska-Sieskiewicz; M Szmitkowski; S Sierakowski
Journal:  Z Rheumatol       Date:  2012-04       Impact factor: 1.372

2.  The effect on immunoglobulin glycosylation of altering in vivo production of immunoglobulin G.

Authors:  P Jeddi; J Keusch; P M Lydyard; K B Bodman-Smith; M S Chesnutt; D Wofsy; H Hirota; T Taga; P J Delves
Journal:  Immunology       Date:  1999-11       Impact factor: 7.397

Review 3.  Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteins.

Authors:  Yukako Ohyama; Kazuki Nakajima; Matthew B Renfrow; Jan Novak; Kazuo Takahashi
Journal:  Expert Rev Proteomics       Date:  2020-05-28       Impact factor: 3.940

4.  Galactose-extended glycans of antibodies produced by transgenic plants.

Authors:  H Bakker; M Bardor; J W Molthoff; V Gomord; I Elbers; L H Stevens; W Jordi; A Lommen; L Faye; P Lerouge; D Bosch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

Review 5.  Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.

Authors:  P Mark Hogarth; Geoffrey A Pietersz
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

Review 6.  FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications.

Authors:  Kenneth G C Smith; Menna R Clatworthy
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

7.  Capillary (Gel) Electrophoresis-Based Methods for Immunoglobulin (G) Glycosylation Analysis.

Authors:  Samanta Cajic; René Hennig; Robert Burock; Erdmann Rapp
Journal:  Exp Suppl       Date:  2021

8.  Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.

Authors:  Amy W Chung; Max Crispin; Laura Pritchard; Hannah Robinson; Miroslaw K Gorny; Xiaojie Yu; Chris Bailey-Kellogg; Margaret E Ackerman; Chris Scanlan; Susan Zolla-Pazner; Galit Alter
Journal:  AIDS       Date:  2014-11-13       Impact factor: 4.177

Review 9.  Glycosylation as a strategy to improve antibody-based therapeutics.

Authors:  Roy Jefferis
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

10.  Molecular analysis of T-B-NK+ severe combined immunodeficiency and Omenn syndrome cases in Saudi Arabia.

Authors:  Osama Alsmadi; Abdulaziz Al-Ghonaium; Saleh Al-Muhsen; Rand Arnaout; Hasan Al-Dhekri; Bandar Al-Saud; Fadi Al-Kayal; Haya Al-Saud; Hamoud Al-Mousa
Journal:  BMC Med Genet       Date:  2009-11-13       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.